Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SER120 in Nocturia (Open-Label Extension)
NCT00981682Phase 3Completed
- Sponsor
- Serenity Pharmaceuticals
- Start
- Aug 2009
- Primary completion
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of SER120 in nocturia, sponsored by Serenity Pharmaceuticals. Primary endpoint: Mean Serum Sodium at 40 weeks. Started Aug 2009; status: completed.
02
Drugs
SER120
03
Conditions
nocturia
Beyond the preview
Go deeper on NCT00981682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00981682.